LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Kodu・Aktsiate loetelu・Embecta Corp

Embecta Corp

Suletud

SektorTervishoid

13.84 3.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.29

Max

13.91

Põhinäitajad
By Trading Economics
Sissetulek	22M 46M
Müük	37M 296M
P/E Sektori keskmine	9.451 77.256
Dividenditootlus	4.5
Kasumimarginaal	15.398
Töötajad	2,100
EBITDA	48M 111M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+23.3% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	4.50% 2.33%
Järgmine tulemuste avaldamine	25. nov 2025
Järgmine aktsia dividendi kuupäev (ex-date)	5. dets 2025

Turustatistika
By TradingEconomics
Turukapital	213M 785M
Eelmine avamishind	10.48
Eelmine sulgemishind	13.84

Uudiste sentiment

By Acuity

50%

165 / 374 Pingereas Healthcare

Embecta Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. nov 2025, 23:51 UTC

Tulu

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5. nov 2025, 23:10 UTC

Tulu

DBS Third Quarter Net Dips 2.0%

5. nov 2025, 22:55 UTC

Tulu

Arm Holdings 2Q Profit Climbs on Record Demand

5. nov 2025, 22:23 UTC

Tulu

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5. nov 2025, 23:52 UTC

Tulu

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5. nov 2025, 23:49 UTC

Tulu

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5. nov 2025, 23:49 UTC

Tulu

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5. nov 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5. nov 2025, 23:42 UTC

Market Talk

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5. nov 2025, 23:12 UTC

Tulu

Nutrien 3Q Adj EPS 97c >NTR.T

5. nov 2025, 23:11 UTC

Tulu

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5. nov 2025, 23:10 UTC

Tulu

Nutrien 3Q Sales $6.01B >NTR.T

5. nov 2025, 23:10 UTC

Market Talk

Tulu

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5. nov 2025, 23:10 UTC

Tulu

Nutrien 3Q EPS 96c >NTR.T

5. nov 2025, 23:04 UTC

Tulu

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5. nov 2025, 23:03 UTC

Market Talk

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5. nov 2025, 22:55 UTC

Market Talk

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5. nov 2025, 22:55 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5. nov 2025, 22:51 UTC

Tulu

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5. nov 2025, 22:50 UTC

Tulu

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5. nov 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5. nov 2025, 22:43 UTC

Market Talk

Tulu

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5. nov 2025, 22:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. nov 2025, 22:36 UTC

Market Talk

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5. nov 2025, 22:20 UTC

Market Talk

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5. nov 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5. nov 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5. nov 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Responds to Delaware Chancery Court Ruling

5. nov 2025, 22:01 UTC

Tulu

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5. nov 2025, 22:01 UTC

Tulu

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Võrdlus sarnastega

Hinnamuutus

Embecta Corp Prognoos

Hinnasiht

By TipRanks

23.3% tõus

12 kuu keskmine prognoos

Keskmine 16.67 USD 23.3%

Kõrge 25 USD

Madal 11 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Embecta Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Embecta Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

165 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.